Cargando…
Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
BACKGROUND: Tumor cells before and after epidermal growth-factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy might display different characteristics. The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP)...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043805/ https://www.ncbi.nlm.nih.gov/pubmed/24920920 http://dx.doi.org/10.2147/OTT.S62639 |
_version_ | 1782318994790809600 |
---|---|
author | Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Hsu, Kuo-Hsuan Yu, Chong-Jen Liao, Wei-Yu Tsai, Chi-Ren Tsai, Meen-Hsin Yu, Sung-Liang Su, Kang-Yi Chen, Jeremy JW Chen, Hsuan-Yu Chang, Gee-Chen |
author_facet | Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Hsu, Kuo-Hsuan Yu, Chong-Jen Liao, Wei-Yu Tsai, Chi-Ren Tsai, Meen-Hsin Yu, Sung-Liang Su, Kang-Yi Chen, Jeremy JW Chen, Hsuan-Yu Chang, Gee-Chen |
author_sort | Tseng, Jeng-Sen |
collection | PubMed |
description | BACKGROUND: Tumor cells before and after epidermal growth-factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy might display different characteristics. The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP) in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. MATERIALS AND METHODS: Advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma receiving PP as first-line chemotherapy were enrolled retrospectively in two medical centers of Taiwan. The objective of this study was to compare objective response rate (ORR), disease-control rates (DCR), progression-free survival (PFS), and overall survival (OS) of PP in patients with and without prior EGFR TKI therapy. RESULTS: In total, 105 patients were analyzed. Sixty-one patients (58.1%) had prior EGFR TKI therapy and used PP as second-line treatment. The other 44 patients (41.9%) received PP as first-line therapy. ORRs of PP in patients with and without prior EGFR TKI therapy were 24.6% and 38.6%, respectively (P=0.138). DCRs of the two groups were 62.3% and 65.9%, respectively (P=0.837). The median PFS (6.1 versus 6.1 months, P=0.639) and OS (34.4 versus 32.3 months, P=0.394) were comparable between the groups with and without prior EGFR TKI therapy. In a subgroup analysis of patients with prior EGFR TKI therapy, there was no significant association between the efficacy of first-line EGFR TKI and the outcome of subsequent PP therapy. CONCLUSION: Our results suggested that prior EGFR TKI therapy would not influence the efficacy of subsequent PP therapy in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. |
format | Online Article Text |
id | pubmed-4043805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-40438052014-06-11 Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Hsu, Kuo-Hsuan Yu, Chong-Jen Liao, Wei-Yu Tsai, Chi-Ren Tsai, Meen-Hsin Yu, Sung-Liang Su, Kang-Yi Chen, Jeremy JW Chen, Hsuan-Yu Chang, Gee-Chen Onco Targets Ther Original Research BACKGROUND: Tumor cells before and after epidermal growth-factor receptor (EGFR) tyrosine-kinase inhibitor (TKI) therapy might display different characteristics. The aim of this study was to evaluate the influence of prior EGFR TKI therapy on the efficacy of subsequent pemetrexed plus platinum (PP) in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. MATERIALS AND METHODS: Advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma receiving PP as first-line chemotherapy were enrolled retrospectively in two medical centers of Taiwan. The objective of this study was to compare objective response rate (ORR), disease-control rates (DCR), progression-free survival (PFS), and overall survival (OS) of PP in patients with and without prior EGFR TKI therapy. RESULTS: In total, 105 patients were analyzed. Sixty-one patients (58.1%) had prior EGFR TKI therapy and used PP as second-line treatment. The other 44 patients (41.9%) received PP as first-line therapy. ORRs of PP in patients with and without prior EGFR TKI therapy were 24.6% and 38.6%, respectively (P=0.138). DCRs of the two groups were 62.3% and 65.9%, respectively (P=0.837). The median PFS (6.1 versus 6.1 months, P=0.639) and OS (34.4 versus 32.3 months, P=0.394) were comparable between the groups with and without prior EGFR TKI therapy. In a subgroup analysis of patients with prior EGFR TKI therapy, there was no significant association between the efficacy of first-line EGFR TKI and the outcome of subsequent PP therapy. CONCLUSION: Our results suggested that prior EGFR TKI therapy would not influence the efficacy of subsequent PP therapy in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma. Dove Medical Press 2014-05-23 /pmc/articles/PMC4043805/ /pubmed/24920920 http://dx.doi.org/10.2147/OTT.S62639 Text en © 2014 Tseng et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Tseng, Jeng-Sen Yang, Tsung-Ying Chen, Kun-Chieh Hsu, Kuo-Hsuan Yu, Chong-Jen Liao, Wei-Yu Tsai, Chi-Ren Tsai, Meen-Hsin Yu, Sung-Liang Su, Kang-Yi Chen, Jeremy JW Chen, Hsuan-Yu Chang, Gee-Chen Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma |
title | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma |
title_full | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma |
title_fullStr | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma |
title_full_unstemmed | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma |
title_short | Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma |
title_sort | prior egfr tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with egfr-mutant lung adenocarcinoma |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4043805/ https://www.ncbi.nlm.nih.gov/pubmed/24920920 http://dx.doi.org/10.2147/OTT.S62639 |
work_keys_str_mv | AT tsengjengsen prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT yangtsungying prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT chenkunchieh prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT hsukuohsuan prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT yuchongjen prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT liaoweiyu prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT tsaichiren prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT tsaimeenhsin prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT yusungliang prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT sukangyi prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT chenjeremyjw prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT chenhsuanyu prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma AT changgeechen prioregfrtyrosinekinaseinhibitortherapydidnotinfluencetheefficacyofsubsequentpemetrexedplusplatinuminadvancedchemonaivepatientswithegfrmutantlungadenocarcinoma |